Evidence map›Paper›PMID 39676320›Full record

ArticleClinical endocrinology2025

CSNK2B Mutation: A Rare Cause of IGHD.

Karine Aouchiche, Pauline Romanet, Anne Barlier, Thierry Brue, Morgane Pertuit, Rachel Reynaud, Alexandru Saveanu

Abstract readCase Reports
In one paragraph

Article in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karine AouchicheMultidisciplinary Pediatric Department, Aix Marseille Univ, APHM, INSERM, MMG, UMR 1251, La Timone Children's Hospital, Marseille, France.ORCID http://orcid.org/0009-0008-5550-9636
Pauline RomanetAix Marseille Univ, APHM, INSERM, MMG, UMR 1251, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, Marseille, France.
Anne BarlierAix Marseille Univ, APHM, INSERM, MMG, UMR 1251, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, Marseille, France.
Thierry BrueDepartment of Endocrinology, Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa Institute, UMR 1251, La Conception University Hospital, Marseille, France.
Morgane PertuitAssistance-Publique des Hôpitaux de Marseille (AP-HM), La Timone University Hospital, Laboratory of Molecular Biology, Marseille, France.
Rachel ReynaudMultidisciplinary Pediatric Department, Aix Marseille Univ, APHM, INSERM, MMG, UMR 1251, La Timone Children's Hospital, Marseille, France.
Alexandru SaveanuAix Marseille Univ, APHM, INSERM, MMG, UMR 1251, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, Marseille, France.

Funding

This research was made possible through access to the data generated by the 2025 French Genomic Medicine Initiative and the technical and bioinformatics support of GCS Auragen consortium. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
6 · The paper itself

Abstract

objectivePoirier-Bienvenu neurodevelopmental syndrome (POBINDS) is a rare neurodevelopmental syndrome, resulting from germline heterozygous CSNKB2 pathogenic variants. The main presentations are severe epilepsy, delayed psychomotor development, and/or profound intellectual disability. More recently, CSNK2B pathogenic variants have been reported in patients with mild intellectual disability and no history of epileptic symptoms. Short stature is present in 66% of patients, in half of these cases due to proven growth hormone deficiency.

methodsWhole genome sequencing (WGS) was performed through a French genomic program for a patient with isolated growth hormone deficiency after negative next generation sequencing (NGS) results. NGS panel analysis of CSNK2B and genes involved in isolated growth hormone deficiency (IGHD) was performed in 44 patients from the Genhypopit network (n = 2144) with growth hormone deficiency (GHD) and intellectual disability (ID) or epilepsy and in a convenience cohort of 68 GHD patients.

resultsWe present the first case of POBINDS presenting mainly as growth delay due to GHD. Genome analysis revealed a de novo pathogenic variant in the translation initiation codon of CSNK2B (c.1 A > G, p.(Met1?)). The patient had mild intellectual disability and subsequent analysis of the patient's clinical history revealed that he had had febrile convulsions, compatible with POBINDS. No CSNK2B pathogenic variants were identified among the 44 selected patients with GHD and ID or epilepsy, or in a convenience cohort of 68 patients with GHD.

conclusionAlthough rare, pediatricians should be aware that POIBNDS syndrome may present as IGHD with mild ID.

Indexed as

Neurodevelopmental DisordersEpilepsyHumansIntellectual DisabilityMutationWhole Genome SequencingCSNK2Bepilepsygrowth hormone deficiencyintellectual disabilityPoirier–Bienvenu Syndrome

Identifiers

PMID39676320
PMCPMC11874222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.